Document is current
Any future updates will be listed below
-
Authors
Baptist, Alan P.
Germain, Guillaume
Klimek, Jacob
Laliberté, François
Schell, Robert C.
Forero-Schwanhaeuser, Sergio
Moore, Alison
Noorduyn, Stephen G.
Paczkowski, Rosirene
-
Funding
Funding for this research was provided by:
GSK (221613)
- License Information
-
More Information
Article History
Received: 16 October 2024
Accepted: 26 November 2024
First Online: 23 December 2024
Declarations
:
: Alan P. Baptist reports grant support from GSK, AstraZeneca, and Teva. Guillaume Germain, Jacob Klimek, François Laliberté, and Robert C. Schell are employees of Analysis Group, a consulting company that has received research funds from GSK to conduct this study. Sergio Forero-Schwanhaeuser, Alison Moore, Stephen G. Noorduyn, and Rosirene Paczkowski are employees of GSK and hold financial equities in GSK. Stephen G. Noorduyn is also a PhD candidate at McMaster University.
: The study was considered exempt research under 45 CFR § 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA): specifically, 45 CFR § 164.514.
